Metraipolis › archive › dc_0a06dcbfa3a9
Dose optimization of inhaled tigecycline in humans to overcome inherent adverse events and maximize bacterial clearance using a physiologically-based… — Europe PMC PMID:42232789
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42232789
- DOI
- 10.3389/ftubr.2026.1762713
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T22:18:48.353Z
- SHA-256 of the archived text
823a7d4d017f234ac6479016d3f17e4269bd830bc844fa47922d9272be544273- Stable URL of this page
https://metraipolis.com/documento/dc_0a06dcbfa3a9
How to cite
Dose optimization of inhaled tigecycline in humans to overcome inherent adverse events and maximize bacterial clearance using a physiologically-based… — Europe PMC PMID:42232789 — Europe PMC (en), https://europepmc.org/article/MED/42232789 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0a06dcbfa3a9 (Metraipolis archive dc_0a06dcbfa3a9, sha256 823a7d4d017f234ac6479016d3f17e4269bd830bc844fa47922d9272be544273)
BibTeX
@misc{dc0a06dcbfa3a9,
title = {Dose optimization of inhaled tigecycline in humans to overcome inherent adverse events and maximize bacterial clearance using a physiologically-based… — Europe PMC PMID:42232789},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42232789},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0a06dcbfa3a9; sha256 823a7d4d017f234ac6479016d3f17e4269bd830bc844fa47922d9272be544273},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42232789. Agents can read the archived copy with the MCP tool read_document.